Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 7, 2024
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Strong cumulative prescriber growth, 45% year-over-year increase
52% year-over-year prescription fill increase; 39% increase since Q1 2024
5.53
-0.81 (-12.78%)
Find more stocks in the Stock Screener
EVOK Latest News and Analysis
